Overview
Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights. The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation. PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults. The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.
Indication
Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.
Associated Conditions
- Chronic Constipation
- Constipation
- Dry Eye Syndrome (DES)
- Dry Eyes
- Occasional Constipation
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/05/29 | Not Applicable | Completed | |||
2025/02/20 | Phase 2 | Not yet recruiting | |||
2025/02/13 | Phase 4 | Recruiting | St. Joseph's Health, New York | ||
2025/02/11 | N/A | Recruiting | Colorado Ophthalmology Associates PC | ||
2025/01/15 | Not Applicable | ENROLLING_BY_INVITATION | Beijing Ditan Hospital | ||
2024/12/11 | Not Applicable | Not yet recruiting | |||
2024/05/01 | Phase 1 | Recruiting | |||
2024/04/15 | Not Applicable | Recruiting | |||
2023/12/07 | Phase 4 | Recruiting | |||
2023/06/09 | Phase 2 | ENROLLING_BY_INVITATION |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Kesin Pharma Corporation | 81033-762 | ORAL | 17 g in 17 g | 6/9/2025 | |
Lupin Pharmaceuticals,Inc. | 43386-090 | ORAL | 236 g in 274.31 g | 12/20/2016 | |
Nexgen Pharma, Inc. | 0722-6921 | ORAL | 17 g in 1 1 | 8/10/2011 | |
Novel Laboratories, Inc. | 40032-090 | ORAL | 236 g in 274.31 g | 2/8/2023 | |
Physicians Total Care, Inc. | 54868-5160 | ORAL | 1 g in 1 g | 5/1/2012 | |
Strides Pharma Science Limited | 64380-769 | ORAL | 420 g in 4 L | 11/9/2022 | |
Lupin Pharmaceuticals,Inc. | 43386-060 | ORAL | 240 g in 278.26 g | 11/16/2017 | |
Physicians Total Care, Inc. | 54868-4233 | ORAL | 210 g in 2 L | 5/11/2011 | |
Novel Laboratories, Inc. | 40032-060 | ORAL | 240 g in 278.26 g | 11/18/2009 | |
Strides Pharma Science Limited | 64380-766 | ORAL | 236 g in 4 L | 11/9/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
FORLAX POWDER FOR ORAL SOLUTION 10 g/sachet | SIN12419P | POWDER, FOR SOLUTION | 10 g/sachet | 9/8/2003 | |
FORTRANS FOR ORAL SOLUTION | SIN09234P | GRANULE, FOR SOLUTION | 64 g | 3/3/1997 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
Polyethylene Glycol Eye Drops | 国药准字HJ20160105 | 化学药品 | 眼用制剂 | 12/3/2020 | |
Macrogol 4000 Powder | 国药准字H20253498 | 化学药品 | 散剂 | 3/4/2025 | |
Macrogol 4000 Powder | 国药准字H20253647 | 化学药品 | 散剂 | 3/18/2025 | |
Macrogol 4000 Powder | 国药准字H20253591 | 化学药品 | 散剂 | 3/11/2025 | |
Macrogol 4000 Powder | 国药准字H20244574 | 化学药品 | 散剂 | 7/30/2024 | |
Macrogol 4000 Powder | 国药准字H20223308 | 化学药品 | 散剂 | 5/10/2022 | |
Macrogol 4000 Powder | 国药准字HJ20171247 | 化学药品 | 散剂 | 8/31/2022 | |
Macrogol 4000 Powder | 国药准字H20243040 | 化学药品 | 散剂 | 1/9/2024 | |
Macrogol 4000 Powder | 国药准字H20050809 | 化学药品 | 散剂 | 4/7/2020 | |
Macrogol 4000 Powder | 国药准字H20080092 | 化学药品 | 散剂 | 9/9/2022 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
SYSTANE ULTRA LUBRICANT EYE DROPS PRESERVATIVE FREE | N/A | alcon hong kong ltd | N/A | N/A | 5/21/2012 |
ISOCOLAN POWDER FOR ORAL SOLUTION | N/A | N/A | N/A | 8/19/2024 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
MOVICOL JUNIOR CHOCOLATE FLAVOUR powder for oral solution sachet | 207698 | Medicine | A | 4/3/2013 | |
MACROVIC FLAVOURED JUNIOR powder for oral solution sachet | 220580 | Medicine | A | 2/27/2014 | |
MACROVIC JUNIOR powder for oral solution sachet | 220582 | Medicine | A | 2/27/2014 | |
MOVICOL FLAVOUR FREE powder for oral solution sachet | 181834 | Medicine | A | 4/4/2011 | |
LAX-SACHETS HALF powder for oral solution sachet | 202203 | Medicine | A | 10/24/2012 | |
Laxitol | 182402 | Medicine | A | 4/21/2011 | |
OSMOLAX macrogol 3350 1g/g powder for oral solution jar | 203142 | Medicine | A | 11/21/2012 | |
APOHEALTH CONSTIPATION RELIEF WITH ELECTROLYTES powder for oral solution sachet | 485587 | Medicine | A | 4/9/2025 | |
MOVIPREP ORANGE powder for oral solution sachet | 206448 | Medicine | A | 2/27/2013 | |
CLEARGOL LEMON FLAVOUR powder for oral solution sachet | 220588 | Medicine | A | 2/27/2014 |
Help Us Improve
Your feedback helps us provide better drug information and insights.